Трудности постановки диагноза «миеломная болезнь»
Онкология

Трудности постановки диагноза «миеломная болезнь»

Автор: Божкова А. П., терапевт-онколог, ветеринарный госпиталь Айвэна Филлмора, Санкт-Петербург.

Список сокращений:
ИПК – инфекционный перитонит кошек;
ММ – множественная миелома;
ОЛЛ – острый лимфобластный лейкоз;
ХВИ – хронические вирусные инфекции;
ХЛЛ – хронический лимфолейкоз;
ЦК – цельная кровь;
ЭМП – экстрамедуллярная плазмоцитома.

Миеломная болезнь (множественная миелома) относится к плазмоцитарным опухолям, образующимся в результате пролиферации клеток В-клеточной линии дифференцировки.
ММ составляет около 8% всех гемопоэтических опухолей у собак, у кошек частота возникновения и развития ММ неизвестна. Болезнь развивается у животных старшего возраста, породной и половой предрасположенности не выявлено.

Список литературы: 
  1. Qurollo B. A., Balakrishnan N., Cannon C. Z., et al. Co-infection with Anaplasma platys, Bartonella henselae, Bartonella koehlerae and ‘Candidatus Mycoplasma haemominutum’ in a cat diagnosed with splenic plasmacytosis and multiple myeloma, J Feline Med Surg, 16: 713–720, 2014.
  2. Burnett R. C., Blake M. K., Thompson L. J., Avery P. R., Avery A. C. Evolution of a B-cell Lymphoma to Multiple Myeloma after Chemotherapy. J of Vet Intern Med, 18(5): 768–771, 2004.
  3. Radhakrishnan A., Risbon R. E., Patel R. T., Ruiz B., Clifford C. A. Progression of a Solitary Malignant Cutaneous Plasma Cell Tumor to Multiple Myeloma in a Cat. Veterinary Comparative Oncology, 2(1): 36–42, 2004.
  4. Hanna F. Multiple Myelomas in Cats. Journal of Feline Medicine and Surgery, 7(5): 275–287, 2005.
  5. Matus R. E., Leifer C. E., MacEwen E. G. et al. Prognostic factors for multiple myeloma in the dog. J Am Vet Med Assoc, 188(11): 1288–92, Jun 1, 1986.
  6. Patel R. T., Caceres A., French A. F. et al. Multiple myeloma in 16 cats: a retrospective study. Vet Clin Pathol, 34(4): 341–52, Dec 2005. 
  7. Mellor P. J., Haugland S., Murphy S. et al. Myeloma-related disorders in cats commonly present as extramedullary neoplasms in contrast to myeloma in human patients: 24 cases with clinical follow-up. J Vet Intern Med, 20(6): 1376–83, Nov-Dec 2006.
  8. Mellor P. J., Haugland S., Smith K. C. et al. Histopathologic, immunohistochemical, and cytologic analysis of feline myelomarelated disorders: further evidence for primary extramedullary development in cat. Vet Pathol, 45(2): 159–73, Mar 2008.
  9. Jane M. Dobson, B. Duncan X. Lascelles. BSAVA. Manual of Canine and Feline Oncology. 3rd ed., 2011.
  10. Majzoub M. et al. Histopathologic and immunophenotypic characterization of extramedullary plasmacytomas in nine cats. Vet Pathol, 40(3): 249–53, May 2003. 
  11. Schöniger S. et al. Sinonasal plasmacytoma in a cat. J Vet Diagn Invest, 19(5): 573–7, Sep 2007.
  12. Tamura Y., Chambers J. K., Neo S., Goto-Koshino Y., Takagi S., et al. Primary duodenal plasmacytoma with associated primary (amyloid light-chain) amyloidosis in a cat. JFMS Open Rep, 6(2), Sep 21, 2020. 
  13. Greenberg M. J. et al. Intracerebral plasma cell tumor in a cat: a case report and literature review. J Vet Intern Med, 18(4): 581–5, Jul-Aug 2004.
  14. Michau T. M., et al. Intraocular extramedullary plasmacytoma in a cat. Vet Ophthalmol, 6(2): 177–81, Jun 2003. 
  15. Kyriazidou A., Brown P. J., Lucke V. M. Immunohistochemical staining of neoplastic and inflammatory plasma cell lesions in feline tissues. J Comp Pathol, 100(3): 337–41, Apr 1989.
  16. Sheofor S. E., Gamblin R. M., Couto C. G. Hypercalcaemia in two cats with multiple myeloma. J Am Anim Hosp Assoc, 32(6): 503–8, Nov-Dec 1996.
  17. Rosol T. J., Capen C. C. Biology of disease mechanisms of cancer-induced hypercalcaemia. Lab Invest, 67(6): 680–702, Dec 1992.
  18. Hendrix D. V. H., Gelatt K. N., Smith P. J., Brooks D. E., Whittaker C. J. G., Chmielewski N. T. Ophthalmic disease as the presenting complaint in five dogs with multiple myeloma. J Am Anim Hosp Assoc, 34(2): 121–8, Mar-Apr 1998. 
  19. Claire M. Cannon. Clinical Signs, Treatment, and Outcome in Cats with Myeloma-Related Disorder Receiving Systemic Therapy. J Am Anim Hosp Assoc, 51(4): 239–48, Jul-Aug 2015.
  20. Seelig D. M., Perry J. A., Avery A. C., Avery P. R. Monoclonal Gammopathy without Hyperglobulinemia in 2 Dogs with IgA Secretory Neoplasms. Vet Clin Pathol, 39(4): 447–453, 2010.
  21. Grogan T. M. Plasma Cell Myeloma Marrow Diagnosis Including Morphologic and Phenotypic Features. Seminars in Diagnostic Pathology, 20(3): 211–215, 2003.
  22. Burton J. H., Mitchell L., et al. Low-Dose Cyclophosphamide Selectively Decreases Regulatory T Cells and Inhibits Angiogenesis in Dogs with Soft Tissue Sarcoma. J Vet Intern Med, 25(4): 920–926, 2011.
  23. Sato M., Yamazaki J. et al. Evaluation of Cytoreductive Efficacy of Vincristine, Cyclophosphamide, and Doxorubicin in Dogs with Lymphoma by Measuring the Number of Neoplastic Lymphoid Cells with Real-Time Polymerase Chain Reaction. J Vet Intern Med, 25(2): 285–291, 2011.
  24. Warry E., Hansen R. J., Gustafson D. L., Lana S. E. Pharmacokinetics of Cyclophosphamide after Oral and Intravenous Administration to Dogs with Lymphoma. J Vet Intern Med, 25(4): 903–908, 2011.
  25. Mitchell L., Thamm D. H., Biller B. J. Clinical and Immunomodulatory Effects of Toceranib Combined with Low-Dose Cyclophosphamide in Dogs with Cancer. J Vet Intern Med, 26(2): 355–362, 2012.
  26. Jaillardon L., Fournell-Fleury C. Waldenström’s Macroglobulinemia in a Dog with a Bleeding Diathesis. Vet Clin Pathol, 40(3): 351–355, 2011.
  27. Fernández R., Chon E. Comparison of two melphalan protocols and evaluation of outcome and prognostic factors in multiple myeloma in dogs. J Vet Intern Med, 32: 1060–69, 2018.
  28. Tani H., Miyamoto R., Miyazaki T. et al. A feline case of multiple myeloma treated with bortezomib. BMC Vet Res, 18: 384, 2022.